Media coverage about Intellipharmaceutics International (NASDAQ:IPCI) (TSE:I) has been trending somewhat positive on Friday, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Intellipharmaceutics International earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news headlines about the company an impact score of 100 out of 100, indicating that recent media coverage is extremely likely to have an effect on the company’s share price in the near term.
Here are some of the headlines that may have effected Accern’s analysis:
- Intellipharmaceutics International Inc. (NASDAQ:IPCI) Expected to Announce Quarterly Sales of $4.21 Million (americanbankingnews.com)
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of IntelliPharmaCeutics International Inc. – (IPCI) (money.ca)
- Intellipharmaceutics International shares tumble 46% after FDA advisory committees decision (proactiveinvestors.co.uk)
- Unusual Activity Sighted in IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Shares (footballhebdo.com)
- Brokers Release Average Price Target Of 9.08 On Intellipharmaceutics International Inc. (IPCI) (hoyentv.com)
Several equities research analysts have commented on IPCI shares. Maxim Group reissued a “buy” rating and set a $6.00 price target on shares of Intellipharmaceutics International in a research report on Friday, June 30th. Zacks Investment Research raised shares of Intellipharmaceutics International from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a research report on Monday, April 17th. Finally, Aegis cut shares of Intellipharmaceutics International from a “buy” rating to a “hold” rating and cut their price target for the stock from $8.00 to $2.00 in a research report on Wednesday, April 12th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company’s stock. Intellipharmaceutics International presently has a consensus rating of “Hold” and an average price target of $3.63.
Shares of Intellipharmaceutics International (NASDAQ:IPCI) traded up 3.68% during midday trading on Friday, hitting $1.41. 1,183,413 shares of the stock were exchanged. Intellipharmaceutics International has a 1-year low of $1.19 and a 1-year high of $3.35. The stock’s market capitalization is $43.11 million. The firm’s 50 day moving average is $2.33 and its 200-day moving average is $2.34.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/07/28/somewhat-positive-press-coverage-extremely-likely-to-affect-intellipharmaceutics-international-nasdaqipci-stock-price-updated-updated-updated.html.
Intellipharmaceutics International Company Profile
Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.